AMAG Pharmaceuticals (NASDAQ:AMAG) has settled matters with activist investor Caligan Partners LP who had filed a preliminary consent statement aimed at replacing four board members with candidates who, it believed, would be change agents.
Under the terms of the agreement, the company has
added former Boehringer Ingelheim USA CEO Paul Fonteyne and Caligan
Partner and co-Founder David Johnson to the board, temporarily expanding
membership to 11 prior to the 2020 Annual Meeting. After the
shareholder vote, membership will revert back to nine directors. Caligan
has withdrawn its consent solicitation.
https://seekingalpha.com/news/3504428-amag-pharma-settles-issues-activist-investor
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.